Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.
3.
4.
5.

Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study.

Garnero P, Borel O, Sornay-Rendu E, Duboeuf F, Jeffery R, Woo P, Delmas PD.

Bone. 2002 Jul;31(1):43-50.

PMID:
12110411
7.

Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine.

Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD.

Bone. 1998 Oct;23(4):367-71.

PMID:
9763149
8.

Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study.

Ferrari SL, Karasik D, Liu J, Karamohamed S, Herbert AG, Cupples LA, Kiel DP.

J Bone Miner Res. 2004 Apr;19(4):552-9. Epub 2004 Jan 5.

9.

Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women.

Abrahamsen B, Shalhoub V, Larson EK, Eriksen EF, Beck-Nielsen H, Marks SC Jr.

Bone. 2000 Feb;26(2):137-45.

PMID:
10678408
11.

Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.

Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.

J Bone Miner Res. 2000 Feb;15(2):315-21.

12.

Polymorphisms of the interleukin-6 gene are associated with bone mineral density.

Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH.

Bone. 1997 Jul;21(1):89-92.

PMID:
9213013
14.

Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.

Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V.

Maturitas. 2006 Mar 20;53(4):371-9. Epub 2005 Aug 31.

PMID:
16139450
15.

Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.

Tofteng CL, Kindmark A, Brändström H, Abrahamsen B, Petersen S, Stiger F, Stilgren LS, Jensen JE, Vestergaard P, Langdahl BL, Mosekilde L; Danish Osteoporosis Prevention Study.

Calcif Tissue Int. 2004 Jan;74(1):25-34. Epub 2003 Oct 2.

PMID:
14517714
16.
17.

Estrogen receptor alpha gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom.

Albagha OM, McGuigan FE, Reid DM, Ralston SH.

J Bone Miner Res. 2001 Jan;16(1):128-34.

18.

Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen.

Kobayashi N, Fujino T, Shirogane T, Furuta I, Kobamatsu Y, Yaegashi M, Sakuragi N, Fujimoto S.

Maturitas. 2002 Mar 25;41(3):193-201.

PMID:
11886765
19.

The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.

Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.

Clin Endocrinol (Oxf). 2005 Mar;62(3):349-53.

PMID:
15730418
20.

COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.

MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MH, Ralston SH, Reid DM.

J Bone Miner Res. 2001 Sep;16(9):1634-41.

Supplemental Content

Support Center